| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503788A2 Treatment of alpha-galactosidase a deficiency |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503758A1 Methods of modulating smooth muscle contractility |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1392285B1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 02/09/2005 | EP1370268A4 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 02/09/2005 | EP1349839B1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/09/2005 | EP1280805B1 Novel imidazotriazinones and the use thereof |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP0863896B1 Novel imidazole derivatives, method for preparing same, pharmaceutical compositions and use of said derivatives as endothelin antagonists |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578782A Silicon compounds |
| 02/09/2005 | CN1578772A Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| 02/09/2005 | CN1578767A Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2005 | CN1578762A Process for resolution of tamsulosin and compounds, compositons, and processes associated therewith |
| 02/09/2005 | CN1578761A Process for resolution of tamsulosin |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1575807A Medicine for treating prostatitis and prostatic hypertrophy and preparation and using method thereof |
| 02/09/2005 | CN1188426C Antibodise against phosphorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
| 02/09/2005 | CN1188416C Oxathiepino [6,5-b]dihydropyridines,and related compositions and preparation methods |
| 02/09/2005 | CN1188415C Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5)for treatment of sexual dysfunction |
| 02/09/2005 | CN1188407C Imidazole derivatives with farnesyl transferase to inhibite activity and preparing method thereof |
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188136C Buffered composition for dialysis |
| 02/08/2005 | US6852750 Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors |
| 02/08/2005 | US6852740 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 02/08/2005 | US6852734 Indole wherein A is an oxygen atom or a nitrogen atom which nitrogen atom is optionally substituted with an alkyl group, and (i) R1 and R2 each stand for a hydrogen atom or an alkyl group, independently, or (ii) R1 and R2 as taken together form |
| 02/08/2005 | US6852728 Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |
| 02/08/2005 | US6852726 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852692 Adrenomedullin composition of the present invention may be used to ameliorate a urination disorder. The urination disorder may be a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence and |
| 02/08/2005 | US6852528 Human and mouse uroplakin II gene transcriptional regulatory elements |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/03/2005 | WO2005010534A1 Ep1 receptor antagonists for the treatment of benign prostatic hypertrophy and screening method |
| 02/03/2005 | WO2005009988A1 Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| 02/03/2005 | WO2005009480A2 Implants containing codrugs |
| 02/03/2005 | WO2005009445A1 A1 adenosine receptor antagonists |
| 02/03/2005 | WO2003064606A3 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026996 A taxane such as paclitaxel or docetaxel joined by a hydrolyzable bond to one or more oligomers having a polyethylene glycol moiety; amphiphilic drug conjugate with improved water solubility without drastic increase in molecular weight |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026954 Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026926 N, N'-disubstituted piperazine compounds and their use as analgesics |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026905 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026889 Treating acne, seborrhea, hirsutism, alopecia, mastodynia, prostate hyperplasia and carcinoma, virilization syndromes in the female, early puberty, use in inhibition of sexual aggressiveness in the male, male contraception |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026822 Human 3 relaxin |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2531491A1 Agonist polypeptide of receptor for zot and zonulin |
| 02/02/2005 | EP1502601A1 Use of neurotoxin therapy for treatment of urinary retention |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501835A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501830A1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501826A2 Substituted indoles as alpha-1 agonists |
| 02/02/2005 | EP1501817A1 Imidazolinylmethyl aralkylsulfonamides |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501794A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| 02/02/2005 | EP1501793A1 Tamsulosin derivative |
| 02/02/2005 | EP1501787A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501535A1 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 02/02/2005 | EP1501517A1 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501514A2 Protein kinase modulators and methods of use |
| 02/02/2005 | EP1501513A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501495A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 02/02/2005 | EP1501485A1 High drug load tablet |
| 02/02/2005 | EP1351980A4 Peptides for activation and inhibition of delta pkc |
| 02/02/2005 | EP1303521B1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 02/02/2005 | EP1221490B1 Recombinant adenoviral vectors and their utilization in the treatment of liver cirrhosis |
| 02/02/2005 | EP1165534B1 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 02/02/2005 | EP1124779B1 Vitamin d analogues |
| 02/02/2005 | EP0851769B1 Gene therapy using ovine adenoviral vectors |
| 02/02/2005 | CN1575291A Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 02/02/2005 | CN1575290A Pyrimidine derivatives and pharmaceutical compositions containing that compounds |
| 02/02/2005 | CN1575289A 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same |